ocrelizumab (Q2013780)

From Wikidata
Jump to navigation Jump to search
anti-CD20 monoclonal antibody under development for treatment of B cell leukemia and multiple sclerosis
  • 2H7
  • R-1594
  • RG-1594
  • PR-070769
  • Ocrevus
edit
Language Label Description Also known as
English
ocrelizumab
anti-CD20 monoclonal antibody under development for treatment of B cell leukemia and multiple sclerosis
  • 2H7
  • R-1594
  • RG-1594
  • PR-070769
  • Ocrevus

Statements

has use
medication
0 references
has part(s)
carbon
0 references

Identifiers

HSDB ID
8371
1 reference
stated in
Hazardous Substances Data Bank
HSDB ID
8371
publication date
28 October 2019
title
Ocrelizumab (English)
retrieved
10 May 2021
LiverTox ID
Ocrelizumab
0 references
ATC code
L04AA36
0 references
RxNorm ID
1876366
0 references
UNII
A10SJL62JY
0 references
Freebase ID
/m/027yysd
0 references
UMLS CUI
C1882138
0 references
 
edit
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  Retrieved from "https://www.wikidata.org/w/index.php?title=Q2013780&oldid=1972241925"